Data calculated by Finbold has estimated the value of COVID-19 vaccines administered within the European Union and European Economic Area countries is $746 m (€624.93 m) as of March 17, 2021.
Pfizer/BioNTech accounts for the highest value at $620 m, followed by Moderna at $69 m, while AstraZeneca holds the third spot at $33 m million. Sinopharm (BBIBV-CorV) vaccine has a value of $19 m, followed by Sputnik V at €1.19 million.
The value is for 64,534,641 total vaccine doses distributed from the manufacturers. Pfizer/BioNTech dominates with 43,412,284 for administered doses or 67.2% of the share. AstraZeneca is second at 15,866,627, representing a share of 25.5%. A total of 3,841,815 Moderna vaccines have been distributed, accounting for 5.9% of the total share.
Vaccine from other unknown manufacturers is third at 717,915 representing 1.15%. Sinopharm (BBIBV-CorV) occupies the fourth spot at 550,000 (0.88%), and Sputnik V (0.23%)
The authors of the report said: "Although the EU/EEA region appears not to have an issue with the financial aspects in acquiring the vaccines, each manufacturer's price is in line with the urgent global health emergency aimed at promoting widespread vaccination. Despite the vaccine supply presenting a perfect opportunity for making profits, companies like AstraZeneca have committed not to financially benefit from the pandemic setting cheap prices, contributing to its popularity."
Roughly three months into the vaccine rollout, the report claims, the region is still struggling due to supply constraints, political infighting, and confusion among the public.
